Entecavir (anhydrous) is guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2′-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme’s activity, although it has no activity against HIV. It is used to treat chronic hepatitis B. Among its listed roles, it functions as a EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral drug. It belongs to the class of 2-aminopurines, an oxopurine, a primary alcohol and a secondary alcohol. It is grouped under the following drug class(es): DNA polymerase inhibitors, Nucleosides and Reverse Transcriptase Inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Baraclude and anhydrous entecavir. Its PubChem CID is 135398508.
Entecavir
| CAS No | 142217-69-4 |
|---|---|
| Molecular Formula | C12H15N5O3 |
| Molecular Weight | 277.28 g/mol |
| Synonyms | 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Entecavir (anhydrous) is guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus.
The listed CAS number is 142217-69-4.
The listed molecular formula is C12H15N5O3.
The listed molecular weight is 277.28 g/mol.
2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one.
The source lists Baraclude and anhydrous entecavir.